5109115 Monoclonal antibody specific for bombesin
1
504 PATENT ABSTRACTS 5109115 5109133 MONOCLONAL ANTIBODY SPECIFIC FOR BOMBESIN ANTIBIOTIC TRIENOMYCINS AND THEIR PRODUCTION Frank F Cuttitta, John Minna assigned to The United States of America as represented by the Secretary of the Dept of Health & Human Ser- vices The present invention discloses anti-bombesin monoclonal antibody and a method of detecting autocrine growth factor. A method and kit for screening and controlling growth of human SCLC has also been disclosed. 5109116 IMMUNOSUPPRESSIVE GLYCOPROTEIN Shinji Funayama, Yokohama, Japan assigned to The Kitasato Institute Novel compounds of the formula See Patent.for Chemical Structure wherein R is hexa- hydrobenzoyl, isovaleryl or 2-methylbutyryl, and pharmaceutically acceptable salts thereof. The novel compounds designated as Trienomy- cins A, B and C are produced by culturing a microorganism belonging to genus Streptomy- ces, specifically Streptomyces sp. 82-16 FERM BP-939 in a medium, accumulating the new com- pounds in the medium and isolating the new compounds therefrom, and if required converted to a salt thereof. These compounds have anti- tumor activity and cytocidal activity. Peter D Arkwright, Raymond A Dwek, Christopher W G Redman, Graham A Rook, Thomas W Rademacher, Oxford, United King- dom assigned to Monsanto Company The disclosure describes novel immunosuppres- sive agents isolated from syncytiotrophoblast microvilli membranes by preparing a minutely subdivided and solubilized preparation of said membranes and isolating the unreduced N- linked oligosaccharides from an extract of the preparation. 5109122 5110587 IMMUNOGENIC COMPOSITION COMPRISING SYNTHETICALLY MODIFIED VACCINIA VIRUS Enzo Paoletti, Dennis Panicali assigned to Health Research Incorporated Vaccines containing vaccinia virus synthetically modified to contain DNA sequences not naturally occurring in vaccinia virus and pro- voking an immunological response thereto in host animals inoculated with said vaccines. ANTIBIOTICS, DEXYLOSYLBENANOMICIN B 5110588 Tomio Takeuchi, Takeshi Hara, Masa Hamada, Shinichi Kondo, Masaji Sezaki, Haruo Yamamoto, Shuichi Gomi, Tokyo, Japan as- signed to Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Two new antibiotics which are now nominated as benanomicin A and benanomicin B, respec- tively, are fermentatively produced by the cul- tivation of a new microorganism, designated as MHI93-16F4 strain, of Actinomycetes. Benanomicins A and B each show antifungal ac- tivity and are useful as a therapeutic antifungal agent. A new compound, dexylosylbenanomiein B is now produced by chemical conversion of benanomicin B, and this semi-synthetic anti- biotic also shows antifungal activity and is useful as a therapeutic antifungal agent. COMPOSITE SALMONELLA E. COLI, VIBRIO CHOLERAE VACCINE STRAINS Renato Morona, Stephen R Attridge, Aberfoyle Park, Australia assigned to Enterovax Limited Composite bacterial strains useful as vaccines for the prophylactic treatment of enteric diseases are hybrids of Salmonella and E. coil in which E. coli-derived lipopolysaccharide cores expressed in a Salmonella organism serve as a scaffold upon which the O-antigen of yet another patho- genic bacterial species, such as Vibrio cholerae is constructed. Such strains, methods of their pro- duction, vaccine compositions comprising these strains, and methods of treating enteric disease with these vaccine compositions, are disclosed.
Transcript of 5109115 Monoclonal antibody specific for bombesin
504 PATENT ABSTRACTS
5109115 5109133
M O N O C L O N A L A N T I B O D Y S P E C I F I C F O R B O M B E S I N
A N T I B I O T I C T R I E N O M Y C I N S A N D T H E I R P R O D U C T I O N
Frank F Cuttitta, John Minna assigned to The United States of America as represented by the Secretary of the Dept of Health & Human Ser- vices
The present invention discloses anti-bombesin monoclonal antibody and a method of detecting autocrine growth factor. A method and kit for screening and controlling growth of human SCLC has also been disclosed.
5109116
I M M U N O S U P P R E S S I V E G L Y C O P R O T E I N
Shinji Funayama, Yokohama, Japan assigned to The Kitasato Institute
Novel compounds of the formula See Patent.for Chemical Structure wherein R is hexa- hydrobenzoyl, isovaleryl or 2-methylbutyryl, and pharmaceutically acceptable salts thereof. The novel compounds designated as Trienomy- cins A, B and C are produced by culturing a microorganism belonging to genus Streptomy- ces, specifically Streptomyces sp. 82-16 FERM BP-939 in a medium, accumulating the new com- pounds in the medium and isolating the new compounds therefrom, and if required converted to a salt thereof. These compounds have anti- tumor activity and cytocidal activity.
Peter D Arkwright, Raymond A Dwek, Christopher W G Redman, Graham A Rook, Thomas W Rademacher, Oxford, United King- dom assigned to Monsanto Company
The disclosure describes novel immunosuppres- sive agents isolated from syncytiotrophoblast microvilli membranes by preparing a minutely subdivided and solubilized preparation of said membranes and isolating the unreduced N- linked oligosaccharides from an extract of the preparation.
5109122
5110587
I M M U N O G E N I C C O M P O S I T I O N C O M P R I S I N G S Y N T H E T I C A L L Y
M O D I F I E D V A C C I N I A V I R U S
Enzo Paoletti, Dennis Panicali assigned to Health Research Incorporated
Vaccines containing vaccinia virus synthetically modified to contain DNA sequences not naturally occurring in vaccinia virus and pro- voking an immunological response thereto in host animals inoculated with said vaccines.
A N T I B I O T I C S , D E X Y L O S Y L B E N A N O M I C I N B 5110588
Tomio Takeuchi, Takeshi Hara, Masa Hamada, Shinichi Kondo, Masaji Sezaki, Haruo Yamamoto, Shuichi Gomi, Tokyo, Japan as- signed to Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
Two new antibiotics which are now nominated as benanomicin A and benanomicin B, respec- tively, are fermentatively produced by the cul- tivation of a new microorganism, designated as MHI93-16F4 strain, of Actinomycetes. Benanomicins A and B each show antifungal ac- tivity and are useful as a therapeutic antifungal agent. A new compound, dexylosylbenanomiein B is now produced by chemical conversion of benanomicin B, and this semi-synthetic anti- biotic also shows antifungal activity and is useful as a therapeutic antifungal agent.
C O M P O S I T E S A L M O N E L L A E. C O L I , V I B R I O C H O L E R A E
V A C C I N E S T R A I N S
Renato Morona, Stephen R Attridge, Aberfoyle Park, Australia assigned to Enterovax Limited
Composite bacterial strains useful as vaccines for the prophylactic treatment of enteric diseases are hybrids of Salmonella and E. coil in which E. coli-derived lipopolysaccharide cores expressed in a Salmonella organism serve as a scaffold upon which the O-antigen of yet another patho- genic bacterial species, such as Vibrio cholerae is constructed. Such strains, methods of their pro- duction, vaccine compositions comprising these strains, and methods of treating enteric disease with these vaccine compositions, are disclosed.
